Last reviewed · How we verify
BDB-001 injection
BDB-001 injection is a monoclonal antibody targeting a specific molecular target.
BDB-001 injection is a monoclonal antibody targeting a specific molecular target. Used for Metastatic non-small cell lung cancer.
At a glance
| Generic name | BDB-001 injection |
|---|---|
| Sponsor | Staidson (Beijing) Biopharmaceuticals Co., Ltd |
| Target | Unknown |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
It works by binding to the target and modulating its activity, leading to a therapeutic effect.
Approved indications
- Metastatic non-small cell lung cancer
Common side effects
- Injection site reaction
Key clinical trials
- BDB-001 Phase III Trial in ANCA-Associated Vasculitis (PHASE3)
- Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis (PHASE1, PHASE2)
- Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS (PHASE2, PHASE3)
- A Safety and Tolerability Study of BDB-001 in Mild, Moderate COVID-19 Patients (PHASE1)
- Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) (PHASE1, PHASE2)
- Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) (PHASE2)
- Tolerability and Safety of BDB-001 Injection in Healthy Subjects (PHASE1)
- Safety and Tolerability of BDB-001 Injection in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BDB-001 injection CI brief — competitive landscape report
- BDB-001 injection updates RSS · CI watch RSS
- Staidson (Beijing) Biopharmaceuticals Co., Ltd portfolio CI